Which of the following is beneficial for patient suffering from gyrate atrophy of choroid due to deficiency of enzyme Ornithine trans carbomylase
**Core Concept**
Gyrate atrophy of the choroid is a rare, inherited condition characterized by progressive loss of vision, due to the deficiency of the enzyme **Ornithine aminotransferase**, not Ornithine transcarbamylase. However, the question seems to be referring to a treatment approach related to amino acid metabolism. **Ornithine** plays a crucial role in the urea cycle, and its metabolism is linked to the management of gyrate atrophy.
**Why the Correct Answer is Right**
Since the question is incomplete and doesn't provide options, we'll focus on the general approach to managing gyrate atrophy. An **arginine-restricted diet** is often beneficial because it reduces the substrate for ornithine production, thereby decreasing ornithine levels in the blood, which is thought to be toxic to the retina.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific option provided, we cannot directly address why it is incorrect.
**Option B:** Similarly, without the specific details, we cannot comment on its accuracy.
**Option C:** And **Option D:** The same applies to these options.
**Clinical Pearl / High-Yield Fact**
A key point in managing gyrate atrophy is reducing **ornithine** levels, and an **arginine-restricted diet** is a common approach. Early intervention can help slow the progression of the disease.
**Correct Answer:** Unfortunately, without the provided options, a specific correct answer cannot be given based on the initial query.